Stockreport

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Patient enrollment completed October 2024 Topline results exp [Read more]